Business Context and Reporting Period
This Form 8-K is filed by Flex Pharma, Inc. (not Decoy Therapeutics Inc.) on June 14, 2019. The filing reports on a special meeting of stockholders held on this date regarding a pending merger with Salarius Pharmaceuticals, LLC. The meeting was adjourned due to a lack of quorum and is scheduled to reconvene on July 12, 2019.
Key Financial Metrics
This filing is a current report regarding corporate governance and a merger proposal. It does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity figures for the reporting period.
Material Changes and Voting Status
- Meeting Outcome: The special meeting held on June 14, 2019, was adjourned because a quorum of stockholders was not present.
- Reconvened Meeting: The meeting will be held on July 12, 2019, at 10:00 A.M. local time at Cooley LLP in Boston, MA.
- Voting Support: Approximately 85% of the shares voted to date support the merger with Salarius.
- Advisory Support: Institutional Shareholder Services (ISS) and Glass-Lewis have recommended voting "FOR" the proposals, citing the transaction as offering a better potential outcome than Flex Pharma's standalone business.
Outlook, Risks, and Management Commentary
Management emphasizes that the merger offers significant future potential based on Salarius's clinical pipeline targeting rare, orphan cancers with no targeted treatments. The filing highlights a critical risk: if the merger is not completed, Flex Pharma will likely dissolve, liquidate, or wind up, causing stockholders to lose most of their investment value. The company urges stockholders to vote immediately to avoid this outcome.
Forward-looking statements are subject to risks including the inability to complete the transaction and uncertainties regarding stockholder value creation.
Investor Verification Checklist
- Verify the reconvened meeting date of July 12, 2019, and ensure voting instructions are followed via telephone, Internet, or proxy card.
- Review the definitive proxy statement/prospectus (File No. 333-229666) for detailed terms of the merger with Salarius Pharmaceuticals.
- Confirm the current voting tally prior to the reconvened meeting to assess the likelihood of achieving a quorum and passing the merger.
- Understand the liquidation risk: failure to approve the merger likely results in the dissolution of Flex Pharma and significant loss of investment value.